Hua Medicine - ESG Rating & Company Profile powered by AI
This report of Hua Medicine employs information from across the web as well as from available disclosures by Hua Medicine. This article contains a Q&A table for Hua Medicine. Alternative companies in the scoring peer group for Hua Medicine are displayed.
Hua Medicine in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 4.8, social score of 6.4 and governance score of 5.3.
5.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 751 | Sigilon Therapeutics Inc | 5.8 | High |
| 751 | Predilife SA | 5.8 | High |
| 774 | Hua Medicine | 5.7 | High |
| 774 | Adverum Biotechnologies Inc | 5.7 | High |
| 774 | Dyadic International Inc | 5.7 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Hua Medicine have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Hua Medicine disclose current and historical energy intensity?
Sign up for free to unlockDoes Hua Medicine report the average age of the workforce?
Sign up for free to unlockDoes Hua Medicine reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Hua Medicine disclose its ethnicity pay gap?
Sign up for free to unlockDoes Hua Medicine disclose cybersecurity risks?
Sign up for free to unlockDoes Hua Medicine offer flexible work?
Sign up for free to unlockDoes Hua Medicine have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Hua Medicine disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Hua Medicine conduct supply chain audits?
Sign up for free to unlockDoes Hua Medicine disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Hua Medicine conduct 360 degree staff reviews?
Sign up for free to unlockDoes Hua Medicine disclose the individual responsible for D&I?
Sign up for free to unlockDoes Hua Medicine disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Hua Medicine disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Hua Medicine disclose water use targets?
Sign up for free to unlockDoes Hua Medicine have careers partnerships with academic institutions?
Sign up for free to unlockDid Hua Medicine have a product recall in the last two years?
Sign up for free to unlockDoes Hua Medicine disclose incidents of discrimination?
Sign up for free to unlockDoes Hua Medicine allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Hua Medicine issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Hua Medicine disclose parental leave metrics?
Sign up for free to unlockDoes Hua Medicine disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Hua Medicine disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Hua Medicine disclose the pay ratio of women to men?
Sign up for free to unlockDoes Hua Medicine support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Hua Medicine disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Hua Medicine reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Hua Medicine involved in embryonic stem cell research?
Sign up for free to unlockDoes Hua Medicine disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Hua Medicine disclose its waste policy?
Sign up for free to unlockDoes Hua Medicine report according to TCFD requirements?
Sign up for free to unlockDoes Hua Medicine disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Hua Medicine disclose energy use targets?
Sign up for free to unlockDoes Hua Medicine disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Hua Medicine have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Hua Medicine
These potential risks are based on the size, segment and geographies of the company.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.